

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/935,366	08/22/2001	J. Fernando Bazan	15631-0004801US	1749
28008	7590 05/06/2004		EXAM	INER
DNAX RESEARCH, INC.			MERTZ, PREMA MARIA	
LEGAL DEPARTMENT 901 CALIFORNIA AVENUE			ART UNIT	PAPER NUMBER
PALO ALTO	), CA 94304		1646	
			DATE MAILED: 05/06/2004	1

Please find below and/or attached an Office communication concerning this application or proceeding.

## **Advisory Action**

Application No.	Applicant(s)	
09/935,366	BAZAN, J. FERNANDO	
Examiner	Art Unit	
Prema M Mertz	1646	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 23 April 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

Examination (RCE) in compliance with 37 CFR 1.114.	•
PERIOD FOR REPLY [check either a) or b	)]
a) The period for reply expires 3 months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date s no event, however, will the statutory period for reply expire later than SIX MONTHS from the ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS 706 07(6)	e mailing date of the final rejection.
706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under tee have been filed is the date for purposes of determining the period of extension and the corresponding tee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).	ling amount of the fee. The appropriate extension or reply originally set in the final Office action; or
1. A Notice of Appeal was filed on Appellant's Brief must be filed within 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismi	the period set forth in issal of the appeal.
2. The proposed amendment(s) will not be entered because:	
(a) They raise new issues that would require further consideration and/or se	earch (see NOTE below);
<ul><li>(b) ☐ they raise the issue of new matter (see Note below);</li></ul>	
(c)       they are not deemed to place the application in better form for appeal by issues for appeal; and/or	y materially reducing or simplifying the
(d)  they present additional claims without canceling a corresponding numb	per of finally rejected claims.
NOTE: <u>See attached</u> .	
3. Applicant's reply has overcome the following rejection(s): the rejection under	<u>r 35 USC 251</u> .
4. Newly proposed or amended claim(s) <u>18-24</u> would be allowable if submitted canceling the non-allowable claim(s).	in a separate, timely filed amendment
5. ☑ The a) ☐ affidavit, b) ☐ exhibit, or c) ☒ request for reconsideration has been application in condition for allowance because: <u>See attached</u> .	n considered but does NOT place the
6. The affidavit or exhibit will NOT be considered because it is not directed SOI raised by the Examiner in the final rejection.	LELY to issues which were newly
7. ☑ For purposes of Appeal, the proposed amendment(s) a) ☑ will not be entere explanation of how the new or amended claims would be rejected is provide	
The status of the claim(s) is (or will be) as follows:	
Claim(s) allowed:	
Claim(s) objected to:	
Claim(s) rejected: <u>18-24</u> .	
Claim(s) withdrawn from consideration:	
8. The drawing correction filed on is a) approved or b) disapproved	ed by the Examiner.
9. Note the attached Information Disclosure Statement(s)( PTO-1449) Paper N	lo(s)
10. Other:	
	Prema Ments Prema M Mertz Primary Examiner Art Unit: 1646

Application/Control Number: 09/935,366

Art Unit: 1646

1. The amendment filed on 4/23/2004 proposes amendments that do not comply with 37 CFR 1.173(b), which sets forth the manner of making amendments in reissue applications. A supplemental paper correctly amending the reissue application is required.

Amendments to the claims may only be made as set forth in 37 CFR 1.173(b)(2), as follows:

Subject matter being added to a new claim requires rewriting and underlining of the entire new claim. 37 CFR 1.173(b)(2) and (d).

In the instant application, the amendments submitted on 4/23/2004 are non-compliant because all of the subject matter being added to the new claim 18 has not been underlined i.e. sub-parts "a)" and "b)" of claim 18 have not been underlined. It is requested that in response to this action, pursuant to 37 CFR 1.173(b)(2) and (d), Applicants submit a compliant amendment with proper underlining of the new claim 18.

2. Claim 23 remains rejected under 35 U.S.C. 1 12, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

This rejection is maintained for reasons of record set forth at page 4 of the previous Office action (3/25/04).

Claim 23, is rejected as improperly dependent on claim 18. For example, claim 23 recites "comprises the mature coding portion of SEQ ID NO:1 or 3", which limitation is broader than the limitations of independent claim 18. In column 15, lines 26-31 and column 16, lines 35-50, the instant specification discloses that fusion polypeptides between IL-B30s and other homologous or heterologous proteins encompass gene fusion partners including β-galactosidase,

Art Unit: 1646

trpE, Protein A, β-lactamase, alpha amylase, alcohol dehydrogenase, yeast alpha mating factor, and detection or purification tags such as a FLAG sequence of His6 sequence. However, claim 18 recites "...polynucleotide encoding a polypeptide of SEQ ID NO:2" which encompasses only SEQ ID NO:2 and no other heterologous polypeptide as encompassed by dependant claim 23. Therefore, claim 23 is broader than independent claim 18. Furthermore, Applicants argue that with respect to claim 23, sub-part (a), since the signal sequence is about 21 amino acids, claim 23 is a smaller polynucleotide that encodes a polypeptide of SEQ ID NO:2 or 4 that lacks the signal sequence. However, contrary to Applicants arguments, claim 18 recites "...polynucleotide encoding a polypeptide of SEQ ID NO:2" which encompasses only SEQ ID NO:2 and not a smaller polypeptide. It is suggested that claim 23 be rewritten as an independent claim in order

to obviate this rejection.

3. Applicants one reminded for any supplemental amendment filed a concurrent out of declaration is required.

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Prema Mertz whose telephone number is (571) 272-0876. The examiner can normally be reached on Monday-Friday from 7:00AM to 3:30PM (Eastern time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached on (571) 271-0871.

Official papers filed by fax should be directed to (703) 872-9306. Faxed draft or informal communications with the examiner should be directed to (571) 273-0876.

Information regarding the status of an application may be obtained from the Patent application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Prima Mury Prema Mertz Ph.D. Primary Examiner Art Unit 1646 May 4, 2004